{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:11:09Z","timestamp":1784005869820,"version":"3.55.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_pp-2024-0034_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare disease with unspecific abdominal symptoms which is therefore often diagnosed at an advanced stage. Curative therapy is delivered by radical surgery, whereas palliative therapy consists of systemic chemotherapy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopically applied chemotherapy which was invented to administer high doses of chemotherapy intraperitoneally in palliative cases of peritoneal malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2024-0034_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The case of a male patient who received PIPAC treatment as individualized approach for unresectable malignant peritoneal mesothelioma is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2024-0034_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patient began treatment with PIPAC procedures in 2017 for MPM that was unresectable because of extensive disease on the small bowel and refused systemic chemotherapy as the usual standard of care. We initiated PIPAC with doxorubicin and cisplatin and could reach stable disease within one year of treatment so that the therapy was discontinued for 2.5 years. Due to progressive disease, PIPAC was continued resulting in stable disease for 2\u00a0years. In total, the patient received 24 PIPAC procedures with no major surgical or toxic side effects over seven years timespan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2024-0034_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We report the case of a patient with MPM who could reach long-term survival of seven years due to a total of 24 PIPAC procedures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/pp-2024-0034","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:08:52Z","timestamp":1748981332000},"page":"111-117","source":"Crossref","is-referenced-by-count":1,"title":["Long-term survival in peritoneal mesothelioma treated with 24 consecutive PIPACs"],"prefix":"10.1515","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0047-368X","authenticated-orcid":false,"given":"Matthias","family":"Mehdorn","sequence":"first","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Competence Center of Diseases of the Peritoneum , University Hospital Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-9391","authenticated-orcid":false,"given":"Boris","family":"Jansen-Winkeln","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Klinik f\u00fcr Allgemein-, Viszeral-, Thorax- und Gef\u00e4\u00dfchirurgie, Klinikum St. Georg , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Rhode","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Niebisch","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusef","family":"Moulla","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Klinik f\u00fcr Allgemein- und Viszeralchirurgie, Klinikum Chemnitz , Chemnitz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Sch\u00f6nherr","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Klinik f\u00fcr Allgemein- und Viszeralchirurgie, Klinikum Chemnitz , Chemnitz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-4553","authenticated-orcid":false,"given":"Patrick Sven","family":"Plum","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[{"name":"University Cancer Center Leipzig, Department of Oncology, Gastroenterology, Hepatology, Pneumology , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-3979","authenticated-orcid":false,"given":"Rene","family":"Thieme","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertraud","family":"Stocker","sequence":"additional","affiliation":[{"name":"University Cancer Center Leipzig, Department of Oncology, Gastroenterology, Hepatology, Pneumology , University Hospital of Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"von Laffert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Leipzig Medical Center , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Gockel","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Klinik f\u00fcr Allgemein- und Viszeralchirurgie, Klinikum Magdeburg , Magdeburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigmar","family":"Stelzner","sequence":"additional","affiliation":[{"name":"Department of Visceral, Transplant, Thoracic and Vascular Surgery , University Hospital of Leipzig , Leipzig , Germany"},{"name":"Competence Center of Diseases of the Peritoneum , University Hospital Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025092318543929523_j_pp-2024-0034_ref_001","doi-asserted-by":"crossref","unstructured":"Karpes, JB, Shamavonian, R, Dewhurst, S, Cheng, E, Wijayawardana, R, Ahmadi, N, et al.. Malignant peritoneal mesothelioma: an in-depth and up-to-date review of pathogenesis, diagnosis, management and future directions. Cancers 2023;15. https:\/\/doi.org\/10.3390\/cancers15194704.","DOI":"10.3390\/cancers15194704"},{"key":"2025092318543929523_j_pp-2024-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Kusamura, S, Kepenekian, V, Villeneuve, L, Lurvink, RJ, Govaerts, K, De Hingh, I, et al.. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47:36\u201359. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.011.","DOI":"10.1016\/j.ejso.2020.02.011"},{"key":"2025092318543929523_j_pp-2024-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Kim, J, Bhagwandin, S, Labow, DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017;5:236. https:\/\/doi.org\/10.21037\/atm.2017.03.96.","DOI":"10.21037\/atm.2017.03.96"},{"key":"2025092318543929523_j_pp-2024-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Liu, S, Staats, P, Lee, M, Alexander, HR, Burke, AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014;46:604\u20139. https:\/\/doi.org\/10.1097\/pat.0000000000000181.","DOI":"10.1097\/PAT.0000000000000181"},{"key":"2025092318543929523_j_pp-2024-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Harmon, RL, Sugarbaker, PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3. https:\/\/doi.org\/10.1186\/1477-7800-2-3.","DOI":"10.1186\/1477-7800-2-3"},{"key":"2025092318543929523_j_pp-2024-0034_ref_006","doi-asserted-by":"crossref","unstructured":"Yasar, S, Yilmaz, F, Utkan, G, Algin, E, Bayram, D, Tamam, S, et al.. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol 2024;31:6228\u201336. https:\/\/doi.org\/10.1245\/s10434-024-15506-3.","DOI":"10.1245\/s10434-024-15506-3"},{"key":"2025092318543929523_j_pp-2024-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Alaklabi, S, Roy, AM, Skitzki, JJ, Iyer, R. Immunotherapy in malignant\u00a0peritoneal mesothelioma (review). Mol Clin Oncol 2023;18:31. https:\/\/doi.org\/10.3892\/mco.2023.2627.","DOI":"10.3892\/mco.2023.2627"},{"key":"2025092318543929523_j_pp-2024-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Reymond, MA, Hu, B, Garcia, A, Reck, T, K\u00f6ckerling, F, Hess, J, et al.. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc 2000;14:51\u20135. https:\/\/doi.org\/10.1007\/s004649900010.","DOI":"10.1007\/s004649900010"},{"key":"2025092318543929523_j_pp-2024-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Solass, W, Kerb, R, Murdter, T, Giger-Pabst, U, Strumberg, D, Tempfer, C, et al.. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025092318543929523_j_pp-2024-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Nielsen, M, Graversen, M, Ellebaek, SB, Kristensen, TK, Fristrup, C, Pfeiffer, P, et al.. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. J\u00a0Clin Pathol 2021;74:19\u201324. https:\/\/doi.org\/10.1136\/jclinpath-2020-206607.","DOI":"10.1136\/jclinpath-2020-206607"},{"key":"2025092318543929523_j_pp-2024-0034_ref_011","doi-asserted-by":"crossref","unstructured":"Gockel, I, Jansen-Winkeln, B, Haase, L, Rhode, P, Mehdorn, M, Niebisch, S, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study. J\u00a0Gastric Cancer 2018;18:379\u201391. https:\/\/doi.org\/10.5230\/jgc.2018.18.e37.","DOI":"10.5230\/jgc.2018.18.e37"},{"key":"2025092318543929523_j_pp-2024-0034_ref_012","doi-asserted-by":"crossref","unstructured":"Orgad, R, Bakrin, N, Bonnefoy, I, Villeneuve, L, Alyami, M, Alhadeedi, O, et al.. Number of pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatments is associated with longer survival: analysis of a large prospective cohort of patients with unresectable peritoneal surface malignancies. Ann Surg 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006447.","DOI":"10.1097\/SLA.0000000000006447"},{"key":"2025092318543929523_j_pp-2024-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U, Demtroder, C, Falkenstein, TA, Ouaissi, M, Gotze, TO, Rezniczek, GA, et al.. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 2018;18:442. https:\/\/doi.org\/10.1186\/s12885-018-4363-0.","DOI":"10.1186\/s12885-018-4363-0"},{"key":"2025092318543929523_j_pp-2024-0034_ref_014","doi-asserted-by":"crossref","unstructured":"Jansen-Winkeln, B, Eberth, J, Moulla, Y, Mehdorn, M, Niebisch, S, Schierle, K, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study. J\u00a0Cancer Res Clin Oncol 2023;149:1331\u201341. https:\/\/doi.org\/10.1007\/s00432-022-04517-w.","DOI":"10.1007\/s00432-022-04517-w"},{"key":"2025092318543929523_j_pp-2024-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Perit 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025092318543929523_j_pp-2024-0034_ref_016","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Pfeiffer, P, Lundell, L, Mortensen, MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 2018;35:103\u20138. https:\/\/doi.org\/10.1007\/s10585-018-9895-9.","DOI":"10.1007\/s10585-018-9895-9"},{"key":"2025092318543929523_j_pp-2024-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Kepenekian, V, P\u00e9ron, J, You, B, Bonnefoy, I, Villeneuve, L, Alyami, M, et al.. Non-resectable malignant peritoneal mesothelioma treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a cohort study. Ann Surg Oncol 2022;29:2104\u201313. https:\/\/doi.org\/10.1245\/s10434-021-10983-2.","DOI":"10.1245\/s10434-021-10983-2"},{"key":"2025092318543929523_j_pp-2024-0034_ref_018","doi-asserted-by":"crossref","unstructured":"Mortensen, MB, Casella, F, Duzgun, O, Glehen, O, Hewett, P, Hubner, M, et al.. Second annual report from the ISSPP PIPAC database. Pleura Perit 2023;8:141\u20136. https:\/\/doi.org\/10.1515\/pp-2023-0047.","DOI":"10.1515\/pp-2023-0047"},{"key":"2025092318543929523_j_pp-2024-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Vogelzang, NJ, Rusthoven, JJ, Symanowski, J, Denham, C, Kaukel, E, Ruffie, P, et al.. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J\u00a0Clin Oncol 2003;21:2636\u201344. https:\/\/doi.org\/10.1200\/jco.2003.11.136.","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2025092318543929523_j_pp-2024-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Baas, P, Scherpereel, A, Nowak, AK, Fujimoto, N, Peters, S, Tsao, AS, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(20)32714-8.","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2025092318543929523_j_pp-2024-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Sgarbura, O, Gourgou, S, Tosi, D, Bakrin, N, Bouazza, N, Delaine, S, et al.. MESOTIP: phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Perit 2019;4:20190010. https:\/\/doi.org\/10.1515\/pp-2019-0010.","DOI":"10.1515\/pp-2019-0010"},{"key":"2025092318543929523_j_pp-2024-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Neumann, V, R\u00fctten, A, Scharmach, M, M\u00fcller, KM, Fischer, M. Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register. Int Arch Occup Environ Health 2004;77:191\u20139. https:\/\/doi.org\/10.1007\/s00420-003-0498-6.","DOI":"10.1007\/s00420-003-0498-6"},{"key":"2025092318543929523_j_pp-2024-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Helm, JH, Miura, JT, Glenn, JA, Marcus, RK, Larrieux, G, Jayakrishnan, TT, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686\u201393. https:\/\/doi.org\/10.1245\/s10434-014-3978-x.","DOI":"10.1245\/s10434-014-3978-x"},{"key":"2025092318543929523_j_pp-2024-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Hubner, M, Somashekhar, SP, Teixeira Farinha, H, Abba, J, Rao, RG, Alyami, M, et al.. Treatment response after pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of colorectal originf. Ann Surg Open 2022;3:e203. https:\/\/doi.org\/10.1097\/as9.0000000000000203.","DOI":"10.1097\/AS9.0000000000000203"},{"key":"2025092318543929523_j_pp-2024-0034_ref_025","doi-asserted-by":"crossref","unstructured":"Sgarbura, O, Eveno, C, Alyami, M, Bakrin, N, Guiral, DC, Ceelen, W, et al.. Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Perit 2022;7:1\u20137. https:\/\/doi.org\/10.1515\/pp-2022-0102.","DOI":"10.1515\/pp-2022-0102"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T18:55:14Z","timestamp":1758653714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,9,24]]}},"alternative-id":["10.1515\/pp-2024-0034"],"URL":"https:\/\/doi.org\/10.1515\/pp-2024-0034","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}